Advangen are currently hiring both in the USA and Australia to strengthen the évolis sales and marketing team. Good to see things are moving.
Seek Australia:
Indeed USA:
I believe that it will be past the September quarter when we'll see the effect of the marketing strategies that are currently only on trial (as per the quarterly announcement). I am hopeful that once the marketing campaigns are being fired up to their full scale, consistent growth can be achieved. There is no reason to exclude the possibility of explosive growth but, personally, I am happy with solid growth and sales that consistenly show the product finds its user base.
It seems that Cellmid is about to cross the line from being a speculative biotech stock to becoming a profitable growth stock.
CDY Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held
